ArticlePublic health action2019
Drug-resistant tuberculosis diagnosis since Xpert
Article in Public health action, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Implementation of GeneXpert for TB Testing in Low- and Middle-Income Countries: A Systematic Review.Global health, science and practice · 2021Pooled it
- A Nomogram Predictive Model for Drug-Resistant Tuberculosis Detection by GeneXpert MTB/RIF Assay in Paediatric Patients.Infection and drug resistance · 2026Article
- Drug-resistant TB in Morobe Province, Papua New Guinea, 2012-2021.Public health action · 2024Article
- Sputum culture contamination and associated characteristics in a diagnostic clinical trial, Papua New Guinea.Public health action · 2024Article
- TB programme outcomes in South Fly District, Papua New Guinea, were maintained through COVID-19.Public health action · 2024Article
- Operational research highlights ongoing challenges for comprehensive TB services in Papua New Guinea.Public health action · 2024Article
- TB burden and diagnostic challenges at Sandaun Provincial Hospital in West Sepik Province of PNG, 2016-2021.Public health action · 2024Article
- Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.Public health action · 2024Article
- Continuous quality improvement in a community-wide TB screening and prevention programme in Papua New Guinea.Public health action · 2024Article
- Evaluation of a population-wide, systematic screening initiative for tuberculosis on Daru island, Western Province, Papua New Guinea.BMC public health · 2024Article
- Article
- Analysis of Drug-Resistant Tuberculosis in Children in Shenyang, China, 2017-2021.Infection and drug resistance · 2023Article
- Critical Consideration of Tuberculosis Management of Papua New Guinea Nationals and Cross-Border Health Issues in the Remote Torres Strait Islands, Australia.Tropical medicine and infectious disease · 2022Article
- Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea.BMC infectious diseases · 2022Article
- Priority Activities in Child and Adolescent Tuberculosis to Close the Policy-Practice Gap in Low- and Middle-Income Countries.Pathogens (Basel, Switzerland) · 2022Article
- Mycoplasma genitalium and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015-2017.Emerging infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
settingXpert
objectiveTo assess the concordance of Xpert with phenotypic drug susceptibility testing (DST) performed at the supranational reference laboratory and to describe the patterns of drug-resistant TB observed.
designThis was a retrospective descriptive study of laboratory data collected from April 2012 to December 2017.
resultsIn 69 months, 1408 specimens with Xpert results were sent for mycobacterial culture and DST; Mycobacterium tuberculosis was cultured from 63% (884/1408) and DST was completed in 99.4%. The concordance between Xpert and culture for M. tuberculosis detection was 98.6%. Of 760 RR-TB cases, 98.7% were detected using Xpert; 98.5% of 620 MDR-TB cases were identified using phenotypic DST. Phenotypic resistance to second-line drugs was detected in 59.4% (522/879) of specimens tested, including 29 with fluoroquinolone resistance; the majority were from the National Capital District and Daru Island.
conclusionThe high concordance between phenotypic DST and Xpert in identifying RR-TB cases supports the scale-up of initial Xpert testing in settings with high rates of drug resistance. However, rapid DST in addition to the detection of RR-TB is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.